This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB05294/identifier/wikipedia/
n10http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB05294/identifier/bindingdb/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/drug/DB05294/identifier/kegg-drug/
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/resource/drugbank/drug/DB05294/identifier/drugbank/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n16http://linked.opendata.cz/resource/drugbank/drug/DB05294/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB05294
rdf:type
n3:Drug
n3:description
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
n3:dosage
n5:271B403B-363D-11E5-9242-09173F13E4C5 n5:271B403A-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Bates D: ZD-6474. AstraZeneca. Curr Opin Investig Drugs. 2003 Dec;4(12):1468-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14763134 # Ton GN, Banaszynski ME, Kolesar JM: Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm. 2013 May 15;70(10):849-55. doi: 10.2146/ajhp120253. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23640345 # Andriamanana I, Gana I, Duretz B, Hulin A: Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 1;926:83-91. doi: 10.1016/j.jchromb.2013.01.037. Epub 2013 Mar 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23562906
n3:group
approved
n3:halfLife
Median half life of 19 days.
n3:indication
Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
owl:sameAs
n10:DB05294
dcterms:title
Vandetanib
adms:identifier
n13:DB05294 n14:D06407 n15:4655 n16:00310-7830-30 n17:Vandetanib
n3:mechanismOfAction
ZD-6474 is a potent and selective inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (REarranged during Transfection) tyrosine kinases. VEGFR- and EGFR-dependent signalling are both clinically validated pathways in cancer, including non-small-cell lung cancer (NSCLC). RET activity is important in some types of thyroid cancer, and early data with vandetanib in medullary thyroid cancer has led to orphan-drug designation by the regulatory authorities in the USA and EU.
n3:patent
n8:8067427 n8:7173038
n3:routeOfElimination
About 69% was recovered following 21 days after a single dose of vandentanib. 44% was found in feces and 25% in urine.
n3:synonym
ZD6474 4-BROMO-2-fluoro-N-[(4e)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4(1H)-ylidene]aniline N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine Zactima ZD 6474 4-quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-
n3:volumeOfDistribution
Vd of about 7450 L.
n3:proteinBinding
Protein binding of about 90%.
n3:IUPAC-Name
n4:271B4040-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4046-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4045-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4042-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4043-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4044-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4056-363D-11E5-9242-09173F13E4C5 n4:271B403E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B403C-363D-11E5-9242-09173F13E4C5 n4:271B403F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B403D-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:L01XE12
n3:H-Bond-Acceptor-Count
n4:271B404C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B404D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4047-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4048-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B404A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4049-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B404B-363D-11E5-9242-09173F13E4C5
n3:absorption
Slow- peak plasma concentrations reached at a median 6 hours. On multiple dosing, Vandetanib accumulates about 8 fold with steady state reached after around 3 months.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
443913-73-3
n3:Bioavailability
n4:271B4052-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4054-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4055-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4051-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4050-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4053-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4041-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B404E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B404F-363D-11E5-9242-09173F13E4C5